.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Mallinckrodt
Moodys
Cerilliant
Colorcon
QuintilesIMS
Baxter
Teva
Harvard Business School
Fish and Richardson

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,043,230

« Back to Dashboard

Which drugs does patent 6,043,230 protect, and when does it expire?


Patent 6,043,230 protects VIREAD, ATRIPLA, COMPLERA, STRIBILD, and TRUVADA, and is included in six NDAs. There have been zero Paragraph IV challenges on Truvada, Complera, Viread, and .

Protection for VIREAD has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty patent family members in seventeen countries.

Summary for Patent: 6,043,230

Title: Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Abstract:Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure -OC(R.sup.2).sub.2 OC(O) X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, axido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR.sup.3. The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy or prophylaxis. Embodiments are particularly useful when administered orally.
Inventor(s): Arimilli; Murty N. (Fremont, CA), Cundy; Kenneth C. (Belmont, CA), Dougherty; Joseph P. (New York, NY), Kim; Choung U. (San Carlos, CA), Oliyai; Reza (San Ramon, CA), Stella; Valentino J. (Lawrence, KS)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:09/314,606
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Gilead Sciences IncVIREADtenofovir disoproxil fumaratePOWDER;ORAL022577-001Jan 18, 2012RXYesYes► Subscribe► Subscribe► SubscribeY
GileadATRIPLAefavirenz; emtricitabine; tenofovir disoproxil fumarateTABLET;ORAL021937-001Jul 12, 2006RXYesYes► Subscribe► Subscribe► SubscribeY
Gilead Sciences IncCOMPLERAemtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarateTABLET;ORAL202123-001Aug 10, 2011RXYesYes► Subscribe► Subscribe► SubscribeY
Gilead Sciences IncSTRIBILDcobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarateTABLET;ORAL203100-001Aug 27, 2012RXYesYes► Subscribe► Subscribe► SubscribeY
GileadTRUVADAemtricitabine; tenofovir disoproxil fumarateTABLET;ORAL021752-002Mar 10, 2016RXYesNo► Subscribe► Subscribe► SubscribeY
GileadTRUVADAemtricitabine; tenofovir disoproxil fumarateTABLET;ORAL021752-003Mar 10, 2016RXYesNo► Subscribe► Subscribe► SubscribeY
GileadTRUVADAemtricitabine; tenofovir disoproxil fumarateTABLET;ORAL021752-004Mar 10, 2016RXYesNo► Subscribe► Subscribe► SubscribeY
GileadTRUVADAemtricitabine; tenofovir disoproxil fumarateTABLET;ORAL021752-001Aug 2, 2004ABRXYesYes► Subscribe► Subscribe► SubscribeY
Gilead Sciences IncVIREADtenofovir disoproxil fumarateTABLET;ORAL021356-002Jan 18, 2012RXYesNo► Subscribe► Subscribe► SubscribeY
Gilead Sciences IncVIREADtenofovir disoproxil fumarateTABLET;ORAL021356-003Jan 18, 2012RXYesNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,043,230

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,922,695 Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability► Subscribe
RE38333 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability► Subscribe
6,069,249 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability► Subscribe
5,977,089 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,043,230

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria240339► Subscribe
Australia3897097► Subscribe
Australia713374► Subscribe
Canada2261619► Subscribe
China100384859► Subscribe
China101239989► Subscribe
China1244200► Subscribe
Germany122005000041► Subscribe
Germany122008000033► Subscribe
Germany69722004► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Merck
Dow
Daiichi Sankyo
Boehringer Ingelheim
Federal Trade Commission
McKinsey
US Department of Justice
Farmers Insurance
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot